# N4 Pharma pleased with initial in vitro results from new SARS-COV-2 plasmid

- Link: https://www.directorstalkinterviews.com/n4-pharma-pleased-with-initial-in-vitro-results-from-new-sars-cov-2-plasmid/4121022234
- Published: 2021-09-14T07:06:21+01:00
- Author: Giles

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has provided a further
update on its current _in vivo_ work streams due to commence shortly with Evotec.

As announced on 24 August 2021, the Company has now successfully completed the amplification
and initial testing of a new SARS-COV-2 plasmid at Evotec and finalised the scope
of the _in vivo_ study. The first step in this new study was to test the _in vitro_
performance of the new plasmid. The optimised Nuvec®, together with the new SARS-
COV-2 plasmid has demonstrated an improved response in terms of transfection and
SARS-COV-2 Spike protein secretion in HEK 293 cells, a commonly used human cell 
line. In addition, the Nuvec®/SARS-COV-2 DNA complex demonstrated a dose-related
SARS-COV-2 Spike protein production. These _in vitro_ results provide a positive
platform for the commencement of the _in vivo_ work beginning this month which is
expected to last six to eight weeks with an additional two to three weeks for analysis.

Nanomerics’s wider _in vivo_ study, as announced on 20 May 2021, has now validated
the results seen from their earlier pilot study, showing an improvement through 
the use of newly formulated and dried Nuvec®. The findings of this work will now
be adopted in all future work undertaken to ensure all studies are performed using
well dispersed Nuvec® formulations.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:**
> “The Board is very pleased with these initial _in vitro_ results from the new 
> SARS-COV-2 plasmid which confirms Nuvec® is capable of producing results in this
> area and demonstrate a material improvement on previous results with an earlier
> plasmid.
> “We are very excited to commence the _in vivo_ work using this SARS-COV-2 plasmid
> alongside the MTA (Material Transfer Agreement) work already in place with a potential
> partner in this area. The aim of the study is to demonstrate the potential of 
> using Nuvec® to develop plasmid DNA vaccines using much lower doses than those
> already approved or are in development and also not requiring refrigeration.”

Share on:
